Ratings by Goldman Sachs (Graig Suvannavejh,)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/1/2021 | Intra-Cellular Therapies | ITCI | Maintain | Buy (N/A) |
|
Details | ||
| 12/10/2020 | Intra-Cellular Therapies | ITCI | New Coverage | Buy (N/A) |
25.80 (53.00) |
105.43% | Details |
